My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Incyte Corporation - Common Stock (NQ:INCY)

98.77 -0.14 (-0.14%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate ↗

September 27, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...

Via Benzinga

Expert Ratings For Incyte ↗

September 23, 2021

Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America ↗

September 23, 2021

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer ↗

September 23, 2021

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

September 23, 2021

Deutsche Bank reduced the price target for FedEx Corporation (NYSE:

Via Benzinga

Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD ↗

September 22, 2021

The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for...

Via Benzinga

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

September 22, 2021

From Incyte

Via Business Wire

Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start ↗

September 22, 2021

Find out what held these laggards back.

Via The Motley Fool

Topics Stocks

Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis ↗

September 22, 2021

The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate...

Via Benzinga

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

September 21, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada ↗

September 20, 2021

Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

Price Over Earnings Overview: Incyte ↗

September 14, 2021

In the current market session, Incyte Inc. (NASDAQ:INCY) is trading at $72.46, after a 0.1% gain. However, over the past month, the stock fell by 4.23%, and in the...

Via Benzinga

Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

September 13, 2021

From Incyte

Via Business Wire

FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know ↗

September 02, 2021

The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR...

Via Benzinga

AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly ↗

September 01, 2021

AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq.

Via Investor's Business Daily

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗

August 31, 2021

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...

Via Benzinga

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration ↗

August 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...

Via Benzinga

Topics Intellectual Property

Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval ↗

August 27, 2021

The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (...

Via Benzinga

Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

August 26, 2021

From Incyte

Via Business Wire

For Hedge Funds, This Is The Worst 6 Months Since The Financial Crisis: Here's Why ↗

August 21, 2021

Via Talk Markets

Week In Review: Sino Biological Stages $772 Million IPO On ChiNext Exchange ↗

August 21, 2021

Sino Biological, a Beijing company that offers biological research reagents to global markets, completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock...

Via Talk Markets

Topics Initial Public Offering

BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial ↗

August 19, 2021

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation...

Via Benzinga

Incyte to Present at Upcoming Investor Conference

August 17, 2021

From Incyte

Via Business Wire

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.